ObjectiveTo explore the diagnostic value of radiomics model based on magnetic resonance T2-weighted imaging for predicting the recurrence of acute pancreatitis.MethodsWe retrospectively collected 190 patients with acute pancreatitis (AP), including 122 patients with initial acute pancreatitis (IAP) and 68 patients with recurrent acute pancreatitis (RAP). At the same time, the clinical characteristics of the two groups were collected. They were randomly divided into training group and validation group in the ratio of 7:3. One hundred thirty-four cases in the training group, including 86 cases of IAP and 48 cases of RAP. There were 56 cases in the validation group, including 36 cases of IAP and 20 cases of RAP. Least absolute shrinkage and selection operator (LASSO) were used for feature screening. Logistic regression was used to establish the radiomics model, clinical model and combined model for predicting AP recurrence. The predictive ability of the three models was evaluated by the area under the curve (AUC). The recurrence risk in patients with AP was assessed using the nomogram.ResultsThe AUCs of radiomics model in training group and validation group were 0.804 and 0.788, respectively. The AUCs of the combined model in the training group and the validation group were 0.833 and 0.799, respectively. The AUCs of the clinical model in training group and validation group were 0.677 and 0.572, respectively. The sensitivities of the radiomics model, combined model, and clinical model were 0.646, 0.691, and 0.765, respectively. The specificities of the radiomics model, combined model, and clinical model were 0.791, 0.828, and 0.590, respectively. There was no significant difference in AUC between the radiomics model and the combined model for predicting RAP (p = 0.067). The AUCs of the radiomics model and combined model were greater than those of the clinical model (p = 0.008 and p = 0.007, respectively).ConclusionsRadiomics features based on magnetic resonance T2WI could be used as biomarkers to predict the recurrence of AP, and radiomics model and combined model can provide new directions for predicting recurrence of acute pancreatitis.
To investigate the predictive value of radiomics based on T1-weighted contrast-enhanced MRI (CE-MRI) in forecasting the recurrence of acute pancreatitis (AP). A total of 201 patients with first-episode of acute pancreatitis were enrolled retrospectively (140 in the training cohort and 61 in the testing cohort), with 69 and 30 patients who experienced recurrence in each cohort, respectively. Quantitative image feature extraction was obtained from MR contrast-enhanced late arterial-phase images. The optimal radiomics features retained after dimensionality reduction were used to construct the radiomics model through logistic regression analysis, and the clinical characteristics were collected to construct the clinical model. The nomogram model was established by linearly integrating the clinically independent risk factor with the optimal radiomics signature. The five best radiomics features were determined by dimensionality reduction. The radiomics model had a higher area under the receiver operating characteristic curve (AUC) than the clinical model for estimating the recurrence of acute pancreatitis for both the training cohort (0.915 vs. 0.811, p = 0.020) and testing cohort (0.917 vs. 0.681, p = 0.002). The nomogram model showed good performance, with an AUC of 0.943 in the training cohort and 0.906 in the testing cohort. The radiomics model based on CE-MRI showed good performance for optimizing the individualized prediction of recurrent acute pancreatitis, which provides a reference for the prevention and treatment of recurrent pancreatitis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.